These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563 [TBL] [Abstract][Full Text] [Related]
4. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE J Virol; 2018 May; 92(9):. PubMed ID: 29467319 [TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098 [TBL] [Abstract][Full Text] [Related]
6. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643 [TBL] [Abstract][Full Text] [Related]
7. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422 [TBL] [Abstract][Full Text] [Related]
8. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. Ruwona TB; Giang E; Nieusma T; Law M J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471 [TBL] [Abstract][Full Text] [Related]
9. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595 [TBL] [Abstract][Full Text] [Related]
10. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development. Pierce BG; Felbinger N; Metcalf M; Toth EA; Ofek G; Fuerst TR Viruses; 2024 May; 16(5):. PubMed ID: 38793684 [TBL] [Abstract][Full Text] [Related]
12. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677 [TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope. Pierce BG; Boucher EN; Piepenbrink KH; Ejemel M; Rapp CA; Thomas WD; Sundberg EJ; Weng Z; Wang Y J Virol; 2017 Oct; 91(20):. PubMed ID: 28794021 [TBL] [Abstract][Full Text] [Related]
14. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725 [TBL] [Abstract][Full Text] [Related]
15. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875 [TBL] [Abstract][Full Text] [Related]
16. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476 [TBL] [Abstract][Full Text] [Related]
17. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001 [TBL] [Abstract][Full Text] [Related]
18. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133 [TBL] [Abstract][Full Text] [Related]
19. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Giang E; Dorner M; Prentoe JC; Dreux M; Evans MJ; Bukh J; Rice CM; Ploss A; Burton DR; Law M Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6205-10. PubMed ID: 22492964 [TBL] [Abstract][Full Text] [Related]
20. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Quadeer AA; Louie RHY; McKay MR Nat Commun; 2019 May; 10(1):2073. PubMed ID: 31061402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]